Cargando…

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Madden, Sarah K., de Araujo, Aline Dantas, Gerhardt, Mara, Fairlie, David P., Mason, Jody M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780693/
https://www.ncbi.nlm.nih.gov/pubmed/33397405
http://dx.doi.org/10.1186/s12943-020-01291-6
_version_ 1783631552866942976
author Madden, Sarah K.
de Araujo, Aline Dantas
Gerhardt, Mara
Fairlie, David P.
Mason, Jody M.
author_facet Madden, Sarah K.
de Araujo, Aline Dantas
Gerhardt, Mara
Fairlie, David P.
Mason, Jody M.
author_sort Madden, Sarah K.
collection PubMed
description c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
format Online
Article
Text
id pubmed-7780693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77806932021-01-05 Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc Madden, Sarah K. de Araujo, Aline Dantas Gerhardt, Mara Fairlie, David P. Mason, Jody M. Mol Cancer Review c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic. BioMed Central 2021-01-04 /pmc/articles/PMC7780693/ /pubmed/33397405 http://dx.doi.org/10.1186/s12943-020-01291-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Madden, Sarah K.
de Araujo, Aline Dantas
Gerhardt, Mara
Fairlie, David P.
Mason, Jody M.
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
title Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
title_full Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
title_fullStr Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
title_full_unstemmed Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
title_short Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
title_sort taking the myc out of cancer: toward therapeutic strategies to directly inhibit c-myc
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780693/
https://www.ncbi.nlm.nih.gov/pubmed/33397405
http://dx.doi.org/10.1186/s12943-020-01291-6
work_keys_str_mv AT maddensarahk takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc
AT dearaujoalinedantas takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc
AT gerhardtmara takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc
AT fairliedavidp takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc
AT masonjodym takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc